Syngene International Ltd

Syngene International has recently adjusted its evaluation amid flat financial performance for the quarter ending December 2024. While the company shows stable operating profit growth and a low debt-to-equity ratio, a decline in promoter confidence and mixed technical indicators suggest a cautious outlook on its long-term growth prospects.

Syngene International has recently adjusted its evaluation, reflecting a stable financial performance for the third quarter of FY24-25. The company has seen modest growth in operating profit over five years, but a decline in profits and reduced promoter stakes raise concerns about its long-term growth potential.

Syngene International has faced a significant decline, with a cumulative drop of 8.27% over two days and a one-month decrease of 9.48%. The stock is trading below key moving averages, indicating potential bearish sentiment, and has underperformed compared to the broader market, represented by the Sensex.

Syngene International, a key player in the Pharmaceuticals & Drugs sector, saw a decline on January 24, 2025, underperforming its sector. The stock opened positively but fell significantly during the session. It is currently trading below all major moving averages, reflecting a bearish trend and challenges in the market.

Syngene International has announced its financial results for Q3 FY24-25, achieving its highest quarterly net sales in five quarters at Rs 943.70 crore. The Profit Before Tax (PBT) reached Rs 162.50 crore, reflecting a significant growth compared to previous quarters, indicating positive trends in the company's performance.

Syngene International experienced a gain on January 23, 2025, yet lagged behind its sector performance. The stock shows a mixed trend in moving averages, being above some while below others. Over the past month, it has outperformed the Sensex, highlighting its resilience amid market fluctuations.

Syngene International experienced a stock price decline on January 15, 2025, underperforming the broader market. The stock exhibited significant intraday volatility, and while it remains above its 200-day moving average, it is below several shorter-term averages, reflecting mixed trends and a cautious outlook.

Syngene International has faced a significant decline in its stock price, underperforming compared to its sector peers. The stock has seen a cumulative decrease over recent days and is currently positioned above its 200-day moving average but below several shorter-term averages, indicating mixed performance.

Syngene International has seen a revision in its score following a notable gain of 3.03% on January 7, 2025. The stock's performance has outpaced its sector, and it has been added to MarketsMOJO's list, indicating a positive adjustment in evaluation amidst a mixed market backdrop.

Syngene International has experienced a recent adjustment in its evaluation, reflecting a decline in stock performance amid broader market trends. Despite this, the company remains a significant player in the pharmaceutical sector, with long-term moving averages indicating stability. The stock has been added to MarketsMOJO's list, highlighting its ongoing relevance.

Syngene International has experienced a notable uptick in its stock performance, prompting a revision in its score by MarketsMOJO. The stock has demonstrated resilience, outperforming the sector and the Sensex, reflecting its strong market position and growth potential in the pharmaceutical industry. Investors are encouraged to monitor its ongoing performance.

Syngene International has experienced a revision in its score following recent stock performance, which has shown a downward trend. Despite this adjustment, the company maintains a strong position in the pharmaceutical sector and has been added to MarketsMOJO's list, indicating ongoing potential for future growth.

Syngene International has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock reached a 52-week high, demonstrating consistent growth and resilience compared to sector benchmarks. Investors are encouraged to monitor Syngene's ongoing developments in the pharmaceutical industry.

Syngene International has recently experienced a notable adjustment in its stock evaluation, reflecting its strong market performance and recent price movements. The stock has reached an all-time high, demonstrating resilience and growth potential. Additionally, it has been added to MarketsMOJO's list, highlighting its favorable position in the pharmaceutical sector.

Syngene International, a leading pharmaceutical and drug company, has seen a decline in its stock price, with a -3.05% drop on November 18, 2024. The stock has been on a downward trend for the past three days, but still remains above its 100-day and 200-day moving averages. In comparison to the Sensex, the stock has underperformed with a -3.05% decline. Despite this, Syngene International remains a largecap company in the industry.

On November 13, 2024, Syngene International's stock saw a -3.0% decline, in line with the sector's performance. Despite this, the stock is trading higher than its long-term moving averages. However, it has underperformed in the short term compared to the overall market. Rated as 'Hold' by MarketsMOJO, the company remains a strong player in the largecap market.

On November 6, 2024, Syngene International's stock saw a 3.1% increase, in line with the sector's performance. The company's stock has been trading higher than its moving averages and has outperformed the Sensex. MarketsMOJO suggests holding onto shares, indicating a positive trend for the company.

On October 29, 2024, Syngene International's stock price closed at Rs 848.85, down by -3.19% from the previous day. The stock's intraday low was Rs 846.05, reflecting a -3.03% decrease. Despite this, the stock's moving averages show a positive trend, with the company's performance in line with the sector's. Over the past month, Syngene International's stock has seen a decline of -4.57%, while the Sensex has seen a decline of -6.61%. MarketsMOJO has given a 'Hold' call for the company, considering its performance and market trends.

On October 24th, 2024, Syngene International's stock gained 4.67%, outperforming the sector by 4.13%. This comes after 5 consecutive days of falling stock prices, indicating a possible trend reversal. The stock also saw high volatility and has received a 'Hold' call from MarketsMOJO. Syngene remains a strong player in the pharmaceutical and drug industry.